The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The administration in May canceled a contract awarded to Moderna for the late-stage development of its bird flu vaccine for humans. When asked about the uncertain regulatory environment in the U.S., ...

The Trump administration recently canceled $766 million in contracts with Moderna to develop and produce an mRNA vaccine against pandemic influenza viruses, including H5N1 avian flu. This is a tragic ...

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

Funding for a potential bird flu vaccine was recently pulled. Moderna expects to end 2025 with $6bn in cash. And analysts see revenue growth resuming in 2026, rising 16% to $2.4bn. Then up another 25% ...

Amid promising signs, officials urged caution, noting that the outbreaks vary by clade, response measures, and social ...

During his Senate confirmation hearings, Health Secretary Robert F. Kennedy Jr. suggested he wouldn’t undermine vaccines. “I ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...